Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

about

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Item

http://www.wikidata.org/entity/Q58796907

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 07 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

@en

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

@nl

type

Item

label

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

@en

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

@nl

prefLabel

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

@en

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

@nl

P1476

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

@en

P2093

Ahmad Awada

http://www.w3.org/2001/XMLSchema#string

Fabrice Journe

http://www.w3.org/2001/XMLSchema#string

François Sales

http://www.w3.org/2001/XMLSchema#string

Ghanem E Ghanem

http://www.w3.org/2001/XMLSchema#string

Mohammad Krayem

http://www.w3.org/2001/XMLSchema#string

Renato Morandini

http://www.w3.org/2001/XMLSchema#string

P2860

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer

Guilty as charged: B-RAF is a human oncogene

P304

31888-31903

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25879

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ahmad Najem

P577

2018-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30159130

http://www.w3.org/2001/XMLSchema#string

P932

6112757

http://www.w3.org/2001/XMLSchema#string